Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab add-on therapy in severe persistent asthma
NL-OMON45129Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in severe asthma and persistent asthma comparing Risankizumab add-on with Placebo add-on (2 arms). Primary endpoint: Time to first asthma worsening. Started Jan 2016; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
severe asthmapersistent asthma
Beyond the preview
Go deeper on NL-OMON45129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45129.